- Advertisement -
HealthHealth TodayAustralia's medicines regulator says MDMA and magic mushrooms may help treat mental...

Australia’s medicines regulator says MDMA and magic mushrooms may help treat mental illness

MDMA and magic mushrooms may help treat mental illness, Australia’s medicines regulator says ahead of its final decision on whether to recognise the drugs.

The Therapeutic Goods Administration looked at studies on PTSD, treatment-resistant depression, obsessive compulsive disorder, social anxiety in adults with autism, and anxiety or depression in the context of life-threatening disease.

‘We conclude that MDMA and psilocybin (the active ingredient in magic mushrooms) may show promise in highly selected populations but only where these medicines are administered in closely clinically supervised settings and with intensive professional support,’ the TGA said on Thursday.

The Therapeutic Goods Administration looked at studies on mental illness, and studies with MDMA found statistically significant improvements for adults with autism and social anxiety

The Therapeutic Goods Administration looked at studies on mental illness, and studies with MDMA found statistically significant improvements for adults with autism and social anxiety

The Therapeutic Goods Administration looked at studies on mental illness, and studies with MDMA found statistically significant improvements for adults with autism and social anxiety 

It examined studies with MDMA that found statistically significant improvements in adults who had autism and social anxiety.

Results for people who had anxiety in the context of life-threatening disease were not significant given low participant numbers.

Studies seeing whether psilocybin was effective in treating OCD symptoms found no significant effect, possibly because of low numbers and a high response to the placebo.

Psilocybin, which is the active ingredient in magic mushrooms (pictured), was found to be as effective as the antidepressant escitalopram for people with anxiety or depression

Psilocybin, which is the active ingredient in magic mushrooms (pictured), was found to be as effective as the antidepressant escitalopram for people with anxiety or depression

Psilocybin, which is the active ingredient in magic mushrooms (pictured), was found to be as effective as the antidepressant escitalopram for people with anxiety or depression

For people with depression or anxiety, psilocybin was as effective as the antidepressant escitalopram.

In February, the TGA handed down an interim decision against recognising the drugs to treat mental illness.

It deferred a final decision pending the review on the drugs’ therapeutic value, risks and benefits.

The report will be considered by the Advisory Committee of Medicines Scheduling on November 3 ahead of a final decision due in early December.

The report by the TGA will be considered by the Advisory Committee of Medicines Scheduling on November 3 ahead of the final decision on whether to recognise the drugs due in December

The report by the TGA will be considered by the Advisory Committee of Medicines Scheduling on November 3 ahead of the final decision on whether to recognise the drugs due in December

The report by the TGA will be considered by the Advisory Committee of Medicines Scheduling on November 3 ahead of the final decision on whether to recognise the drugs due in December

Source: Daily Mail

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Subscribe Today

GET EXCLUSIVE FULL ACCESS TO PREMIUM CONTENT

SUPPORT NONPROFIT JOURNALISM

EXPERT ANALYSIS OF AND EMERGING TRENDS IN CHILD WELFARE AND JUVENILE JUSTICE

TOPICAL VIDEO WEBINARS

Get unlimited access to our EXCLUSIVE Content and our archive of subscriber stories.

Related content

- Advertisement -

Latest article

More article

- Advertisement -